This is a StreetInsider.com Premium Only Page

Chimerix (CMRX) – Company Press Releases

Apr 16, 2024 04:05 PM Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 21, 2024 07:00 AM Chimerix Appoints Marc D. Kozin to Board of Directors

Feb 29, 2024 07:00 AM Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update

Feb 27, 2024 07:00 AM Chimerix to Present at TD Cowen 44th Annual Health Care Conference

Feb 22, 2024 07:00 AM Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024

Dec 29, 2023 07:00 AM Chimerix Appoints Lisa Decker to Board of Directors

Dec 4, 2023 07:00 AM Chimerix Promotes Michelle LaSpaluto to Chief Financial Officer

Nov 24, 2023 07:00 AM Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 16, 2023 07:00 AM Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer

Nov 2, 2023 07:00 AM Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update

Oct 26, 2023 07:00 AM Chimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on November 2, 2023

Sep 5, 2023 07:00 AM Chimerix to Participate in Upcoming Investor Conferences

Aug 16, 2023 10:05 AM Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in "Cancer Discovery"

Aug 3, 2023 07:00 AM Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update

Jul 27, 2023 07:00 AM Chimerix to Report Second Quarter 2023 Financial Results and Provide an Operational Update on August 3, 2023

Jun 27, 2023 04:05 PM Chimerix Announces Promotion of Michael T. Andriole to President and Chief Executive Officer

May 31, 2023 04:01 PM Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference

May 25, 2023 07:00 AM Chimerix to Participate in Cancer Moonshot Brain Cancers Forum on Glioblastoma (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG) at White House

May 4, 2023 07:00 AM Chimerix Reports First Quarter 2023 Financial Results and Provides Operational Update

Apr 27, 2023 07:00 AM Chimerix to Report First Quarter 2023 Financial Results and Provide an Operational Update on May 4, 2023

Apr 18, 2023 04:01 PM Chimerix Announces Presentation of Multiple Imipridone Datasets at American Association for Cancer Research Annual Meeting

Mar 2, 2023 07:00 AM Chimerix Reports Fourth Quarter and Year End 2022 Financial Results and Provides Operational Update

Feb 28, 2023 04:05 PM Chimerix to Present at Cowen and Company 43rd Annual Health Care Conference

Feb 23, 2023 07:00 AM Chimerix to Report Fourth Quarter and Year End 2022 Financial Results and Provide an Operational Update on March 2, 2023

Jan 5, 2023 07:00 AM Chimerix to Present at 41st Annual J.P. Morgan Healthcare Conference

Dec 8, 2022 05:00 PM Chimerix Announces Successful Launch of ONC201 Phase 3 ACTION Study at Society for Neuro-Oncology Conference and Provides Operational Update

Nov 10, 2022 04:30 PM Chimerix Responds to Rubric Capital Management

Nov 10, 2022 09:00 AM Rubric Capital Management Sends Letter to Chimerix Board of Directors

Nov 3, 2022 07:00 AM Chimerix Reports Third Quarter 2022 Financial Results and Provides Operational Update

Oct 27, 2022 04:30 PM Chimerix to Report Third Quarter 2022 Financial Results and Provide an Operational Update on November 3, 2022

Sep 26, 2022 04:05 PM Chimerix Announces Closing of TEMBEXA Sale to Emergent BioSolutions

Sep 6, 2022 07:00 AM Chimerix to Present at H.C. Wainwright 24th Annual Global Investment Conference

Aug 29, 2022 10:45 AM Chimerix Awarded BARDA Contract for TEMBEXA as Medical Countermeasure for Smallpox

Aug 8, 2022 04:01 PM Chimerix Reports Second Quarter 2022 Financial Results and Provides Operational Update

Aug 8, 2022 07:00 AM Chimerix Appoints Christopher L. Jordan as Vice President, Regulatory Affairs

Aug 2, 2022 07:00 AM Chimerix to Present at Wedbush PacGrow Healthcare Conference

Aug 1, 2022 04:01 PM Chimerix to Report Second Quarter 2022 Financial Results and Provide an Operational Update on August 8, 2022

Jun 24, 2022 10:06 AM Chimerix Announces TEMBEXA Procurement Agreement for Approximately $25.3 Million with Public Health Agency of Canada

Jun 23, 2022 09:15 AM Chimerix Announces $9.3 Million International TEMBEXA Procurement Agreement

Jun 1, 2022 04:30 PM Chimerix to Present at Jefferies Global Healthcare Conference

May 17, 2022 04:15 PM Chimerix to Present at H.C. Wainwright Global Investment Conference

May 16, 2022 07:00 AM Chimerix Reports First Quarter 2022 Financial Results and Provides Operational Update

May 16, 2022 06:32 AM Emergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages

May 16, 2022 06:32 AM Emergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages

May 16, 2022 06:30 AM Chimerix Announces Sale of TEMBEXA to Emergent BioSolutions for up to $337.5 Million plus Royalties

May 12, 2022 04:15 PM Chimerix to Participate in Maxim Group Panel Discussion

May 9, 2022 07:00 AM Chimerix to Report First Quarter 2022 Financial Results and Provide an Operational Update on May 16, 2022

Mar 21, 2022 07:00 AM Chimerix to Present at Maxim Group 2022 Virtual Growth Conference

Mar 1, 2022 07:00 AM Chimerix Reports Fourth Quarter and Year End 2021 Financial Results and Provides Operational Update

Feb 28, 2022 07:00 AM Chimerix to Present at Cowen and Company 42nd Annual Health Care Conference